PT2342182E - Derivados de isoquinolinona como antagonistas de nk3 - Google Patents

Derivados de isoquinolinona como antagonistas de nk3

Info

Publication number
PT2342182E
PT2342182E PT97762850T PT09776285T PT2342182E PT 2342182 E PT2342182 E PT 2342182E PT 97762850 T PT97762850 T PT 97762850T PT 09776285 T PT09776285 T PT 09776285T PT 2342182 E PT2342182 E PT 2342182E
Authority
PT
Portugal
Prior art keywords
antagonists
isoquinolinone derivatives
isoquinolinone
derivatives
Prior art date
Application number
PT97762850T
Other languages
English (en)
Inventor
Nikolay Khanzhin
Karsten Juhl
Soren Moller Nielsen
Klaus Baek Simonsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41227186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2342182(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PT2342182E publication Critical patent/PT2342182E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97762850T 2008-09-15 2009-09-11 Derivados de isoquinolinona como antagonistas de nk3 PT2342182E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200801290 2008-09-15
DKPA200900010 2009-01-06

Publications (1)

Publication Number Publication Date
PT2342182E true PT2342182E (pt) 2013-02-11

Family

ID=41227186

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97762850T PT2342182E (pt) 2008-09-15 2009-09-11 Derivados de isoquinolinona como antagonistas de nk3

Country Status (27)

Country Link
EP (1) EP2342182B1 (pt)
JP (1) JP5536776B2 (pt)
KR (1) KR101638641B1 (pt)
CN (1) CN102149685B (pt)
AR (1) AR073511A1 (pt)
AU (1) AU2009291309B2 (pt)
BR (1) BRPI0917245B8 (pt)
CA (1) CA2732612C (pt)
CL (1) CL2011000533A1 (pt)
CO (1) CO6351781A2 (pt)
CY (1) CY1113743T1 (pt)
DK (1) DK2342182T3 (pt)
EA (1) EA021581B1 (pt)
ES (1) ES2399177T3 (pt)
HR (1) HRP20130038T1 (pt)
IL (1) IL210236A (pt)
MX (1) MX2011001786A (pt)
MY (1) MY164998A (pt)
NZ (1) NZ591265A (pt)
PL (1) PL2342182T3 (pt)
PT (1) PT2342182E (pt)
RS (1) RS52674B (pt)
SI (1) SI2342182T1 (pt)
SM (1) SMT201300020B (pt)
TW (1) TWI454461B (pt)
WO (1) WO2010028655A1 (pt)
ZA (1) ZA201103119B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
EA201170074A1 (ru) 2008-06-23 2011-10-31 Х. Лундбекк А/С Изохинолиноновые производные в качестве антагонистов nk3
MX2011004034A (es) 2008-10-20 2011-05-10 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas de nk3.
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) * 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
CN104203919A (zh) 2011-11-09 2014-12-10 艾伯维德国有限责任两合公司 可用作10a型磷酸二酯酶的抑制剂的杂环甲酰胺类
CA3098603A1 (en) * 2018-04-27 2019-10-31 Sojournix, Inc. Polymorphic and amorphous forms of isoquinolinone and methods of use thereof
WO2023152888A1 (ja) * 2022-02-10 2023-08-17 カルナバイオサイエンス株式会社 フルオロイソキノリン化合物およびその製造法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
JP2004525183A (ja) * 2001-04-11 2004-08-19 グラクソスミスクライン・ソシエタ・ペル・アチオニ Nk−3およびnk−2受容体アンタゴニストとしてのキノリン−4−カルボキサミド誘導体
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists

Also Published As

Publication number Publication date
BRPI0917245A2 (pt) 2015-11-10
AR073511A1 (es) 2010-11-10
AU2009291309B2 (en) 2014-07-17
EA021581B1 (ru) 2015-07-30
SI2342182T1 (sl) 2013-04-30
CA2732612C (en) 2016-08-09
CN102149685A (zh) 2011-08-10
IL210236A (en) 2013-08-29
TW201010979A (en) 2010-03-16
NZ591265A (en) 2013-02-22
EP2342182B1 (en) 2012-11-14
ES2399177T3 (es) 2013-03-26
JP2012502069A (ja) 2012-01-26
MX2011001786A (es) 2011-03-29
RS52674B (en) 2013-06-28
PL2342182T3 (pl) 2013-04-30
WO2010028655A1 (en) 2010-03-18
JP5536776B2 (ja) 2014-07-02
MY164998A (en) 2018-02-28
CO6351781A2 (es) 2011-12-20
BRPI0917245B1 (pt) 2020-07-28
CY1113743T1 (el) 2016-06-22
IL210236A0 (en) 2011-03-31
CL2011000533A1 (es) 2011-08-26
BRPI0917245A8 (pt) 2018-08-14
EP2342182A1 (en) 2011-07-13
KR20110059849A (ko) 2011-06-07
TWI454461B (zh) 2014-10-01
ZA201103119B (en) 2012-09-26
CA2732612A1 (en) 2010-03-18
EA201170447A1 (ru) 2011-08-30
CN102149685B (zh) 2015-01-07
HRP20130038T1 (hr) 2013-02-28
AU2009291309A1 (en) 2010-03-18
KR101638641B1 (ko) 2016-07-11
DK2342182T3 (da) 2013-02-04
SMT201300020B (it) 2013-05-06
BRPI0917245B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
ZA201007126B (en) Isoquinolinone derivatives as nk3 antagonists
HUS2200025I1 (hu) C5AR antagonisták
ZA201103119B (en) Isoquinolinone derivatives as nk3 antagonists
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
IL212107A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL209663A0 (en) Isoquinolinone derivatives as nk3 antagonists
ZA201105056B (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
IL213631A0 (en) Isoquinoline derivative
IL187410A0 (en) Quinoline derivatives as nk3 antagonists
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL200781A0 (en) Heterocycles as orexin antagonists
GB0808948D0 (en) Substituted quinazolines
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
IL217759A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
ZA201003169B (en) New non-peptide derivatives as bradykinin b1 antagonists
HK1169992A1 (en) Pyrrolidine derivatives as nk - 3 receptor antagonists nk-3
ZA201005986B (en) Novel heterocycles
GB0808947D0 (en) Substituted quinazolines
GB0808944D0 (en) Substituted quinazolines
IL213763A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
GB0808951D0 (en) Substituted quinazolines
GB0808950D0 (en) Substituted quinazolines
IL213769A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists